Loading…
Doximity, Inc. is projected to rise to $21.73 by 2027, a +7% move from its current price of $20.26. DOCS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $19.57 | $20.25 | $20.96 | -0.03% |
| May 30 | $19.29 | $20.25 | $21.26 | -0.06% |
| May 31 | $19.07 | $20.24 | $21.48 | -0.08% |
| Jun 1 | $18.89 | $20.24 | $21.68 | -0.11% |
| Jun 2 | $18.73 | $20.23 | $21.85 | -0.14% |
| Jun 3 | $18.59 | $20.23 | $22.00 | -0.17% |
| Jun 4 | $18.46 | $20.22 | $22.15 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.46 | $20.22 | $22.15 | -0.20% |
| Week 2 | $17.74 | $20.18 | $22.95 | -0.39% |
| Week 3 | $17.21 | $20.14 | $23.58 | -0.59% |
| Week 4 | $16.76 | $20.10 | $24.11 | -0.78% |
| Week 5 | $16.37 | $20.06 | $24.59 | -0.98% |
| Week 6 | $16.02 | $20.02 | $25.02 | -1.17% |
| Week 7 | $15.71 | $19.98 | $25.42 | -1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems.
The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems.
The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Doximity, Inc. (DOCS) operates in the Healthcare sector and is publicly traded with a current price of $19.94 and a market cap of $3.65B. It holds a rank of 1579 in market listings. The latest price outlook shows a neutral start in 2026 with an average price of $19.94, a 2026 range from $18.01 to $25.05, and a 0% ROI.
From 2027 onward, forecasts shift to a bullish trajectory, with 2027 averaging $21.22 and a max of $29.47 (ROI 6.4%), 2028 averaging $25.21 and a max of $36.58 (ROI 26.4%), and 2029 averaging $27.63 with a max of $41.51 (ROI 38.6%). By 2030 the average is projected at $27.94 with a max of $43.22 (ROI 40.1%).
Looking further, 2031–2035 show continued gains, culminating in 2034 averaging $34.47 with a max of $58.22 (ROI 72.9%) and 2035 averaging $38.59 with a max of $66.32 (ROI 93.5%). The long-range forecast then points to 2040 averaging $47.04 with a max of $86.97 (ROI 135.9%) and 2050 averaging $74.73 with a max of $153.49 (ROI 274.8%).
A major floor 35.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.1% below — buyers have tended to step in here.
The nearest ceiling, 30.6% above — a clean break opens room to run.
A major ceiling 103.7% above — clearing it would confirm fresh momentum.
Key DOCS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DOCS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.79 | Buy | $19.95 | Buy |
| MA 10 | $19.82 | Buy | $20.56 | Sell |
| MA 20 | $22.64 | Sell | $21.70 | Sell |
| MA 50 | $23.25 | Sell | $23.91 | Sell |
| MA 100 | $27.96 | Sell | $29.20 | Sell |
| MA 200 | $44.36 | Sell | $37.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.31 | Neutral |
| Stoch RSI (14) | 39.68 | Neutral |
| CCI (20) | -54.79 | Neutral |
| Williams %R (14) | -73.34 | Info |
| MACD (12,26,9) | -0.32 | Sell |
| ROC (12) | -22.02 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 26.66 | Neutral |
| TRIX (15) | -0.53 | Sell |
| Awesome (5,34) | -3.21 | Sell |
| Ultimate (7,14,28) | 52.95 | Neutral |
| Momentum (10) | -6.19 | Sell |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 19.89 | Buy |
| ADX (14) | 25.46 | Sell |
| ATR (14) | 0.78 | Info |
The 30-day technical picture is bearish. RSI14 is 40, and the short-term trend shows downward pressure.
Key moving averages place near-term resistance and support levels: SMA50 at $23.44 and SMA200 at $44.78. Support is at $18.01 and resistance at $26.45, framing a narrow 30-day range from $15.79 to $25.17. Volatility remains elevated, with annualized volatility at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.01 | $20.26 | $25.69 | 0% | Neutral | |
| $16.80 | $21.73 | $30.02 | +7% | Neutral | |
| $19.09 | $25.57 | $36.89 | +26% | Bullish | |
| $20.57 | $28.38 | $42.35 | +40% | Bullish | |
| $20.17 | $28.58 | $43.89 | +41% | Bullish | |
| $18.52 | $26.89 | $42.33 | +33% | Bullish | |
| $18.67 | $27.73 | $44.65 | +37% | Bullish | |
| $19.25 | $29.22 | $48.01 | +44% | Bullish | |
| $22.92 | $35.52 | $59.44 | +75% | Bullish | |
| $25.35 | $40.08 | $68.24 | +98% | Bullish | |
| $28.09 | $48.67 | $89.04 | +140% | Bullish | |
| $38.56 | $78.70 | $159.66 | +288% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $18.01 | $20.26 | $23.71 | +0.00% |
| June 2026 | $16.37 | $19.34 | $23.46 | -4.55% |
| July 2026 | $16.54 | $19.75 | $24.36 | +2.12% |
| August 2026 | $16.71 | $20.11 | $25.14 | +1.86% |
| September 2026 | $16.10 | $19.52 | $24.65 | -2.97% |
| October 2026 | $15.95 | $19.46 | $24.80 | -0.32% |
| November 2026 | $16.42 | $20.14 | $25.88 | +3.51% |
| December 2026 | $16.08 | $19.83 | $25.69 | -1.53% |
Click any year to see its month-by-month DOCS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, DOCS could reach as high as $25.69, with a base case around $20.26 and support toward $18.01 — roughly 0% from $20.26. Price action looks broadly range-bound.
Expect DOCS to range from $16.80 to $30.02 through 2027. The $21.73 average target implies a +7% move from current prices. That is up +7% on the projected 2026 average. A consolidation phase looks the most probable path here.
The DOCS price prediction for 2028 points to an average of $25.57 (low $19.09, high $36.89) — a potential gain of +26% on today's $20.26. Momentum favours further upside here.
In 2029, DOCS is projected to trade between $20.57 and $42.35, averaging $28.38 — a potential gain of +40% from today's $20.26. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Doximity, Inc.'s 2030 outlook centres on $28.58, within a $20.17 to $43.89 range. That is up +1% on the projected 2029 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2031, DOCS could reach as high as $42.33, with a base case around $26.89 and support toward $18.52 — roughly +33% from $20.26. Buyers look set to stay in control over this stretch.
Expect DOCS to range from $18.67 to $44.65 through 2032. The $27.73 average target implies a +37% move from current prices. That is up +3% on the projected 2031 average. Momentum favours further upside here.
The DOCS price prediction for 2033 points to an average of $29.22 (low $19.25, high $48.01) — a potential gain of +44% on today's $20.26. Buyers look set to stay in control over this stretch.
In 2034, DOCS is projected to trade between $22.92 and $59.44, averaging $35.52 — a potential gain of +75% from today's $20.26. That is up +22% on the projected 2033 average. Momentum favours further upside here.
Doximity, Inc.'s 2035 outlook centres on $40.08, within a $25.35 to $68.24 range. That is up +13% on the projected 2034 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, DOCS could reach as high as $89.04, with a base case around $48.67 and support toward $28.09 — roughly +140% from $20.26. Momentum favours further upside here.
Expect DOCS to range from $38.56 to $159.66 through 2050. The $78.70 average target implies a +288% move from current prices. That is up +62% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DOCS today (≈ 49.358342 DOCS) could be worth
$3,884.49
+$2,884.49 (+288%) by 2050 · US Dollar
Based on the average projected DOCS price of $78.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DOCSwould be worth at today's price.
$1,000 invested in DOCS on May 27, 2025 (≈ 19.193859 DOCS) would be worth
$388.87
-$611.13 (-61.1%) today · 0.39× · US Dollar
Based on a DOCS entry price of $52.1 vs. today's $20.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.86 | $1,020.14 | +2.0% |
| 1 month ago | $24.66 | $821.57 | -17.8% |
| 3 months ago | $25.1 | $807.17 | -19.3% |
| 6 months ago | $51.44 | $393.86 | -60.6% |
| 1 year ago | $52.1 | $388.87 | -61.1% |
| All time (4.9y) ago | $53 | $382.26 | -61.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DOCS forecast.
Our base-case forecast reaches $41.00 around 2040.
Implied market cap at $41.00: $5.41B
The multi-year forecast paints a bullish longer-term path after a neutral start in 2026. The 2026 min, avg, and max are $18.01, $19.94, and $25.05 with an ROI of 0% and sentiment Neutral.
In 2027 the forecast shows an average price of $21.22, a max of $29.47, a min of $16.34, and an ROI of 6.4% with Neutral sentiment. The subsequent years turn progressively more bullish: 2028 avg $25.21, 2029 avg $27.63, and 2030 avg $27.94 with maxes of $36.58, $41.51, and $43.22 and ROIs of 26.4%, 38.6%, and 40.1%, respectively.
The horizon beyond 2030 continues the bullish trend: 2031 avg $26.21, 2032 avg $26.67, 2033 avg $28.40, 2034 avg $34.47 (min $22.02, max $58.22; ROI 72.9%), and 2035 avg $38.59 (min $24.14, max $66.32; ROI 93.5%). The 2040 forecast shows an average of $47.04 with a max of $86.97 (ROI 135.9%), and by 2050 the average reaches $74.73 with a max of $153.49 (ROI 274.8%). These outcomes carry bullish sentiment overall, but as with all forecasts, they are estimates, not guarantees, and depend on market dynamics and company performance.
Tap a question to reveal the answer.
2030 avg price is $27.94, with a min of $19.58 and a max of $43.22, ROI 40.1%; sentiment BULLISH.
Forecast data show Neutral in 2026 and 2027, then BULLISH from 2028 onward, with 2030 avg $27.94 and ROI 40.1%, 2040 avg $47.04 ROI 135.9%, and 2050 avg $74.73 ROI 274.8%. These are estimates and not guarantees.
Yes, the forecast lists 2034 max $58.22 and 2035 max $66.32, with 2040 max $86.97 and 2050 max $153.49, so reaching $50 is possible within these projections.
Current price is $19.94 and market cap is $3.65B.
Bearish sentiment with RSI14 at 40. SMA50 is $23.44 and SMA200 is $44.78. Support is at $18.01 and resistance at $26.45. The 30-day range is $15.79 to $25.17, with annualized volatility of 70%.
Doximity, Inc. Community Discussion
0Share your Doximity, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.